Johannes Oldenburg

Research interests

Publications

• Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2211075

• Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2209226

• Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

  Hämostaseologie · 2021 · https://doi.org/10.1055/a-1469-7481

• Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

  Blood · 2020 · https://doi.org/10.1182/blood.2020009217

• A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

  Blood · 2019 · https://doi.org/10.1182/blood.2019001869

• Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1803550

• Emicizumab Prophylaxis in Hemophilia A with Inhibitors

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1703068

• Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

  Blood · 2016 · https://doi.org/10.1182/blood-2015-09-669234

• Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient's Outcome

  Annals of Surgery · 2016 · https://doi.org/10.1097/sla.0000000000001747

• Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A

  Blood · 2013 · https://doi.org/10.1182/blood-2013-02-483263

• Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

  Blood · 2013 · https://doi.org/10.1182/blood-2012-09-457036

• F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

  Blood · 2012 · https://doi.org/10.1182/blood-2011-09-379453

• Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males

  Human Genetics · 2007 · https://doi.org/10.1007/s00439-007-0430-3

• Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

  Blood · 2007 · https://doi.org/10.1182/blood-2006-11-052373

• Genetic risk factors for inhibitors to factors VIII and IX

  Haemophilia · 2006 · https://doi.org/10.1111/j.1365-2516.2006.01361.x

• Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A

  Blood · 2006 · https://doi.org/10.1182/blood-2006-05-024711

• Haemophilia A: from mutation analysis to new therapies

  Nature Reviews Genetics · 2005 · https://doi.org/10.1038/nrg1617

• VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

  Thrombosis and Haemostasis · 2005 · https://doi.org/10.1160/th05-04-0290

• Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A

  Blood · 2005 · https://doi.org/10.1182/blood-2005-09-3918

• The Genetic Basis of Resistance to Anticoagulants in Rodents

  Genetics · 2005 · https://doi.org/10.1534/genetics.104.040360

• Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

  Nature · 2004 · https://doi.org/10.1038/nature02214

• Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’

  Vox Sanguinis · 1996 · https://doi.org/10.1111/j.1423-0410.1996.tb01346.x

• Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation

  Thrombosis and Haemostasis · 1995 · https://doi.org/10.1055/s-0038-1649954

Current projects

No projects listed.